摘要
二肽基肽酶-4（DPP-4）可能通过灭活胰高血糖素样肽-1、神经肽Y以及调节能量平衡等多种途径影响机体脂质代谢.非酒精性脂肪性肝病（NAFLD）是一种无过量饮酒史,而以肝实质细胞脂肪变性和脂肪贮积为特征的临床综合征,肥胖、高脂血症、胰岛素抵抗在其发生和发展过程中发挥重要作用.DPP-4可能是NAFLD的一种重要调节因子,目前用于2型糖尿病治疗的新型药物DPP-4抑制剂可能在肥胖及NAFLD的控制中发挥重要作用.
Dipeptidyl peptidase-4 （DPP-4） may exert pleiotropic effects on lipid metabolism by inactivating glucagon-like peptide-1 （GLP-1）,neuropeptide Y（NPY） and regulating energy balance.Nonalcoholic fatty liver disease （NAFLD） is a chronic liver injury without a history of alcohol abuse,which characterized by fatty degeneration in liver parenchyma cells and fat storage.Obesity,hyperlipidemia and insulin resistance play important roles in the development and progression of NAFLD.DPP-4 is a key modulator in NAFLD.DPP-4 inhibitors,an emerging class of drugs for treatment of type 2 diabetes mellitus,may play an important role inthe prevention of obesity and NAFLD.
出处
《国际内分泌代谢杂志》
北大核心
2014年第2期112-114,126,共4页
International Journal of Endocrinology and Metabolism
